Integrated profiling of basal and luminal breast cancers

Cancer Research

Volumn 67, Issue 24, 2007, Pages 11565-11575

  Adélaïde, José ^a   Finetti, Pascal ^a   Bekhouche, Ismahane ^a   Repellini, Laetitia ^a   Geneix, Jeannine ^a   Sircoulomb, Fabrice ^a   Charafe Jauffret, Emmanuelle ^a,b,c   Cervera, Nathalie ^a   Desplans, Jérôme ^d   Parzy, Daniel ^d   Schoenmakers, Eric ^e   Viens, Patrice ^b,c   Jacquemier, Jocelyne ^a,b   Birnbaum, Daniel ^a   Bertucci, François ^a,b,c   Chaffanet, Max ^a,b  

^a INSERM   (France)

^b INSTITUT PAOLI CALMETTES   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

^d SERVICE DE SANTÉ DES ARMÉES   (France)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BCL2L2 GENE; BREAST CANCER; CCNE GENE; CHROMOSOME 10P; CHROMOSOME 12P; CHROMOSOME 1Q; CHROMOSOME 8P; COMPARATIVE GENOMIC HYBRIDIZATION; EGFR GENE; ETV6 GENE; FEMALE; FGFR2 GENE; FLT3 GENE; GENE; GENE EXPRESSION PROFILING; HORMAD1 GENE; HUMAN; HUMAN TISSUE; IGF1R GENE; MAJOR CLINICAL STUDY; NOTCH2 GENE; ONCOGENE; PIK3CA GENE; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; ZNF703 GENE;

ADENOCARCINOMA; BREAST NEOPLASMS; CHROMOSOME MAPPING; CHROMOSOMES, HUMAN, PAIR 8; DNA, NEOPLASM; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; NUCLEIC ACID HYBRIDIZATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RNA, NEOPLASM;

EID: 37549006702     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-2536     Document Type: Article

References (50)

1. Charafe-Jauffret E, Ginestier C, Monville F, et al. How to best classify breast cancer: conventional and novel classifications. Int J Oncol 2005;27:1307-13.
2. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000;406:747-52.
3. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98:10869-74.
4. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003;100:8418-23.
5. Bertucci F, Finetti P, Rougemont J, et al. Gene expression profiling identifies molecular subtypes of inflammatory breast cancer. Cancer Res 2005;65: 2170-8.
6. Longo R, Torino F, Gasparini G. Targeted therapy of breast cancer. Curr Pharm Des 2007;13:497-517.
7. Popescu NC, Zimonjic DB. Chromosome and gene alterations in breast cancer as markers for diagnosis and prognosis as well as pathogenetic targets for therapy. Am J Med Genet 2002;115:142-9.
8. Al-Kuraya K, Schraml P, Torhorst J, et al. Prognostic relevance of gene amplifications and coamplifications in breast cancer. Cancer Res 2004;64:8534-40.
9. Bergamaschi A, Kim YH, Wang P, et al. Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer. Genes Chromosomes Cancer 2006;45:1033-40.
10. Chin K, DeVries S, Fridlyand J, et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 2006;10:529-41.
11. Neve RM, Chin K, Fridlyand J, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006;10:515-27.
12. Stransky N, Vallot C, Reyal F, et al. Regional copy number-independent deregulation of transcription in cancer. Nat Genet 2006;38:1386-96.
13. Yao J, Weremowicz S, Feng B, et al. Combined cDNA array comparative genomic hybridization and serial analysis of gene expression analysis of breast tumor progression. Cancer Res 2006;66:4065-78.
14. Vincent-Salomon A, Gruel N, Lucchesi C, et al. Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity. Breast Cancer Res 2007;9:R24.
15. van't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-6.
16. van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999-2009.
17. Abd El-Rehim DM, Ball G, Pinder SE, et al. High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer 2005;116:340-50.
18. Jacquemier J, Ginestier C, Rougemont J, et al. Protein expression profiling identifies subclasses of breast cancer and predicts prognosis. Cancer Res 2005;65:767-79.
19. Livasy CA, Karaca G, Nanda R, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 2006;19:264-71.
20. Charafe-Jauffret E, Monville F, Bertucci F, et al. Moesin is a marker of basal breast cancer. Int J Cancer 2007;121:1779-85.
21. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006;295:2492-502.
22. Ridolfi RL, Rosen PP, Port A, Kinne D, Mike V. Medullary carcinoma of the breast: a clinicopathologic study with 10 year follow-up. Cancer 1977;40:1365-85.
23. Theillet C, Adéla?̈de J, Louason G, et al. FGFRI and PLAT genes and DNA amplification at 8p12 in breast and ovarian cancers. Genes Chromosomes Cancer 1993; 7:219-26.
24. Bertucci F, Finetti P, Cervera N, et al. Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers. Cancer Res 2006;66:4636-44.
25. Irizarry RA, Hobbs B, Collin F, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003;4:249-64.
26. Etienne A, Carbuccia N, Adéla?̈de J, et al. Rearrangements involving 12q in myeloproliferative disorders: possible role of HMGA2 and SOCS2 genes. Cancer Genet Cytogenet 2007;176:80-8.
27. Barrett MT, Scheffer A, Ben-Dor A, et al. Comparative genomic hybridization using oligonucleotide microarrays and total genomic DNA. Proc Natl Acad Sci U S A 2004;101:17765-70.
28. Fridlyand J, Snijders AM, Ylstra B, et al. Breast tumor copy number aberration phenotypes and genomic instability. BMC Cancer 2006;6:96-108.
29. Olshen AB, Venkatraman ES, Lucito R, Wigler M. Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics 2004;5: 557-72.
30. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 1998;95: 14863-8.
31. Snijders AM, Fridlyand J, Mans DA, et al. Shaping of tumor and drug-resistant genomes by instability and selection. Oncogene 2003;22:4370-9.
32. Redon R, Ishikawa S, Fitch KR, et al. Global variation in copy number in the human genome. Nature 2006;444: 444-54.
33. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Stat Soc B Met 1995;57:289-300.
34. Letessier A, Sircoulomb F, Ginestier C, et al. Frequency, prognostic impact, and subtype association of 8p12, 8q24, 11q13, 12p13, 17q12, and 20q13 amplifications in breast cancers. BMC Cancer 2006;6:245.
35. Loi S, Haibe-Kains B, Desmedt C, et al. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol 2007;25:1239-46.
36. Reis-Filho JS, Savage K, Lambros MB, et al. Cyclin D1 protein overexpression and CCND1 amplification in breast carcinomas: an immunohistochemical and chromogenic in situ hybridisation analysis. Mod Pathol 2006; 19:999-1009.
37. Gelsi-Boyer V, Orsetti B, Cervera N, et al. Comprehensive profiling of 8p11-12 amplification in breast cancer. Mol Cancer Res 2005;3:655-67.
38. Huang HE, Chin SF, Ginestier C, et al. A recurrent chromosome breakpoint in breast cancer at the NRG1/neuregulin 1/heregulin gene. Cancer Res 2004; 64:6840-4.
39. Popovici C, Basset C, Bertucci F, et al. Reciprocal translocations in breast tumor cell lines: cloning of a t(3;20) that targets the FHIT gene. Genes Chromosomes Cancer 2002;35:204-18.
40. Letessier A, Garrido-Urbani S, Ginestier C, et al. Correlated break at PARK2/FRA6E and loss of AF-6/ Afadin protein expression are associated with poor outcome in breast cancer. Oncogene 2007;26:298-307.
41. Smith DI, McAvoy S, Zhu Y, Perez DS. Large common fragile site genes and cancer. Semin Cancer Biol 2007;17: 31-41.
42. Letessier A, Ginestier C, Charafe-Jauffret E, et al. ETV6 gene rearrangements in invasive breast carcinoma. Genes Chromosomes Cancer 2005;44:103-8.
43. Coe BP, Ylstra B, Carvalho B, Meijer GA, Macaulay C, Lam WL. Resolving the resolution of array CGH. Genomics 2007;89:647-53.
44. Albertson DG. Gene amplification in cancer. Trends Genet 2006;22:447-55.
45. Wang ZC, Lin M, Wei LJ, et al. Loss of heterozygosity and its correlation with expression profiles in subclasses of invasive breast cancers. Cancer Res 2004; 64:64-71.
46. Moore FL, Jaruzelska J, Fox MS, et al. Human Pumilio-2 is expressed in embryonic stem cells and germ cells and interacts with DAZ (Deleted in AZoospermia) and DAZ-like proteins. Proc Natl Acad Sci U S A 2003;100:538-43.
47. Hyman E, Kauraniemi P, Hautaniemi S, et al. Impact of DNA amplification on gene expression patterns in breast cancer. Cancer Res 2002;62:6240-5.
48. Boehm JS, Zhao JJ, Yao J, et al. Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell 2007;129:1065-79.
49. Wicha MS, Liu S, Dontu G. Cancer stem cells: an old idea - a paradigm shift. Cancer Res 2006;66:1883-90; discussion 1895-6.
50. Reis-Filho JS, Pinheiro C, Lambros MB, et al. EGFR amplification and lack of activating mutations in metaplastic breast carcinomas. J Pathol 2006;209: 445-53.